MedTrace Logo

Use of GI BIOTICS 100B UFC to Improve Intestinal Health in Older Adults

NCT06396728 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 44

Last updated 2024-05-02

No results posted yet for this study

Summary

Type of study: Clinical Trial.

Main objective: To study the effect of daily consumption of the probiotic (GI BIOTICS 100B UFC) on intestinal inflammatory markers, intestinal microbiota, intestinal health, body composition and sports performance in older adults for 8 weeks.

Participant Population/Health Conditions: The study will involve 44 sedentary men with a body mass index \> 25 kg/m2 and aged between 60 and 75 years.

Participants Will:

Be randomised into one of two groups: consumption of a placebo capsule (comparison group) and consumption of GI BIOTICS 100B UFC daily for a period of 8 weeks (experimental group). Provide feces and blood samples before and after the 8-week intervention. Undergo analysis of these samples using advanced techniques to understand the effect of the consumption of the probiotic. Undergo a submaximal stress test and muscle strength will be measured using a handgrip dynamometer.

Conditions

  • Gut Microbiota
  • Gut Health
  • Digestive System
  • Intestinal Inflammation
  • Strength

Interventions

DIETARY_SUPPLEMENT

GI BIOTICS 100B UFC

Consumption of GI BIOTICS 100B UFC.

DIETARY_SUPPLEMENT

Placebo Consumption

Consumption of a placebo capsule.

Sponsors & Collaborators

  • Universidad de Almeria

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
SINGLE
Model
SINGLE_GROUP

Eligibility

Min Age
60 Years
Max Age
75 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-01
Primary Completion
2024-11-30
Completion
2025-03-31

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06396728 on ClinicalTrials.gov